Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah is on track and performing well with its U.S. launch and has potential for strong future growth potential in the medical technology industry. The recent 1Q net-revenue and U.S. sales numbers show that NYXH is meeting and exceeding expectations, and the company's guidance for FY26 revenue only further solidifies their potential for success. With increasing sales forces and the potential for label expansion in 2027, the company has multiple pathways for growth and investor confidence.

Nyxoah is showing early signs of success in their U.S. commercialization with positive growth in account additions and patient submissions for prior authorization. Their disciplined approach to operating expenses and aim for profitability at lower revenues is commendable, but there are concerns around lingering confusion in the physician community regarding coding for their Genio system. Additionally, while their European operations have been strong, the exchange rate and uncertain reimbursement landscape in the U.S. could impact their overall financial performance and limit their potential for expansion. Overall, the positive signs in their early U.S. launch are not enough to overcome the potential risks and uncertainties in the company's future growth and profitability.